HOME › DRUGS › MAVACAMTEN
ACTIVE SUBSTANCE / INN

MAVACAMTEN

Brand name(s): CAMZYOS, Camzyos
FDA LISTED
EMA LISTED
PRESCRIPTION
AUTHORISED
Cardiomyopathy, Hypertrophic
NDA214998
ACTIVE SUBSTANCE
Mavacamten
REGULATORS
FDA · EMA
SPONSORS / MAH
BRISTOL, Bristol-Myers Squibb Pharma EEIG
TOTAL APPLICATIONS
2
FDA APPLICATIONS (DRUGS@FDA)
BRAND NAMEAPPLICATIONSPONSORSTATUS
CAMZYOSNDA214998BRISTOLPrescription
EMA AUTHORISATIONS
PRODUCT NAMEHOLDERSTATUSDATEINDICATION
CamzyosBristol-Myers Squibb Pharma EEIGAuthorised26/06/2023Cardiomyopathy, Hypertrophic

FULL INTELLIGENCE ON MAVACAMTEN

Patent cliffs, clinical trials, pipeline data, AI-enriched regulatory signals — free on PharmaSignal.

OPEN PLATFORM →